NEW YORK (GenomeWeb News) – A new center in Ontario, Canada focused on pharmacogenetic applications for addiction and mental health has been established with a C$19 million (US$19.1 million) investment.

The center, called the Tanenbaum Centre for Pharmacogenetics, is a collaboration between businessman Lawrence Tanenbaum, the Ontario government, and the Centre for Addiction and Mental Health (CAMH) and will support research to accelerate the time it takes to get genetic information to physicians and patients in Ontario.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.